Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
275
-
Total 13F shares, excl. options
-
194M
-
Shares change
-
-3.28M
-
Total reported value, excl. options
-
$1.47B
-
Value change
-
-$33.5M
-
Put/Call ratio
-
0.79
-
Number of buys
-
127
-
Number of sells
-
-139
-
Price
-
$7.59
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q3 2025
327 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q3 2025.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 275 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 194M shares
of 210M outstanding shares and own 92.57% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (21.8M shares), BlackRock, Inc. (21.2M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (12.2M shares), STATE STREET CORP (9.81M shares), Kynam Capital Management, LP (9.39M shares), UBS Group AG (5.97M shares), ALKEON CAPITAL MANAGEMENT LLC (5.46M shares), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (5.23M shares), MORGAN STANLEY (5.2M shares), and GEODE CAPITAL MANAGEMENT, LLC (5.05M shares).
This table shows the top 275 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.